全文获取类型
收费全文 | 4647篇 |
免费 | 492篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 173篇 |
妇产科学 | 61篇 |
基础医学 | 715篇 |
口腔科学 | 125篇 |
临床医学 | 561篇 |
内科学 | 855篇 |
皮肤病学 | 92篇 |
神经病学 | 587篇 |
特种医学 | 147篇 |
外科学 | 515篇 |
综合类 | 63篇 |
一般理论 | 2篇 |
预防医学 | 512篇 |
眼科学 | 38篇 |
药学 | 254篇 |
中国医学 | 1篇 |
肿瘤学 | 407篇 |
出版年
2023年 | 45篇 |
2022年 | 58篇 |
2021年 | 126篇 |
2020年 | 80篇 |
2019年 | 139篇 |
2018年 | 127篇 |
2017年 | 106篇 |
2016年 | 105篇 |
2015年 | 121篇 |
2014年 | 142篇 |
2013年 | 219篇 |
2012年 | 299篇 |
2011年 | 285篇 |
2010年 | 144篇 |
2009年 | 124篇 |
2008年 | 219篇 |
2007年 | 197篇 |
2006年 | 185篇 |
2005年 | 171篇 |
2004年 | 167篇 |
2003年 | 163篇 |
2002年 | 149篇 |
2001年 | 99篇 |
2000年 | 100篇 |
1999年 | 120篇 |
1998年 | 37篇 |
1997年 | 44篇 |
1996年 | 44篇 |
1995年 | 38篇 |
1994年 | 37篇 |
1992年 | 78篇 |
1991年 | 79篇 |
1990年 | 60篇 |
1989年 | 64篇 |
1988年 | 53篇 |
1987年 | 61篇 |
1986年 | 53篇 |
1985年 | 39篇 |
1984年 | 53篇 |
1983年 | 40篇 |
1982年 | 42篇 |
1981年 | 37篇 |
1980年 | 29篇 |
1979年 | 39篇 |
1978年 | 41篇 |
1977年 | 35篇 |
1976年 | 32篇 |
1975年 | 35篇 |
1974年 | 34篇 |
1973年 | 40篇 |
排序方式: 共有5142条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
76.
77.
Markus B Sikkel Carl Hayward Kenneth T MacLeod Sian E Harding Alexander R Lyon 《British journal of pharmacology》2014,171(1):38-54
Therapeutic options that directly enhance cardiomyocyte contractility in chronic heart failure (HF) therapy are currently limited and do not improve prognosis. In fact, most positive inotropic agents, such as β-adrenoreceptor agonists and PDE inhibitors, which have been assessed in HF patients, cause increased mortality as a result of arrhythmia and sudden cardiac death. Cardiac sarcoplasmic reticulum Ca2+-ATPase2a (SERCA2a) is a key protein involved in sequestration of Ca2+ into the sarcoplasmic reticulum (SR) during diastole. There is a reduction of SERCA2a protein level and function in HF, which has been successfully targeted via viral transfection of the SERCA2a gene into cardiac tissue in vivo. This has enhanced cardiac contractility and reduced mortality in several preclinical models of HF. Theoretical concerns have been raised regarding the possibility of arrhythmogenic adverse effects of SERCA2a gene therapy due to enhanced SR Ca2+ load and induction of SR Ca2+ leak as a result. Contrary to these concerns, SERCA2a gene therapy in a wide variety of preclinical models, including acute ischaemia/reperfusion, chronic pressure overload and chronic myocardial infarction, has resulted in a reduction in ventricular arrhythmias. The potential mechanisms for this unexpected beneficial effect, as well as mechanisms of enhancement of cardiac contractile function, are reviewed in this article. 相似文献
78.
79.
Sibyl Wray Brooke Hayward Fernando Dangond Barry Singer 《Expert opinion on drug delivery》2018,15(2):127-135
Background: For interferon beta-1a subcutaneously three times weekly (IFN β-1a SC tiw), administration options include manually injected prefilled syringes; a preassembled, single-use autoinjector; and a reusable autoinjector. This study evaluated patient-perceived ease of use of two injection devices.Research design and methods: REDEFINE, a Phase IV, multicenter crossover study, randomized patients with multiple sclerosis and ≥5 weeks’ IFN β-1a 44 μg SC tiw use to 4 weeks using a single-use autoinjector, then 4 weeks using a reusable autoinjector, or vice versa. The primary endpoint was the proportion rating each ‘easy’ or ‘very easy’, with/without regard to previous device experience.Results: Of 97 randomized patients, 29 had most recent experience with manual injection; 23 with single-use autoinjector; and 45 with reusable autoinjector. 68.4% found using the single-use autoinjector very easy or easy, versus 77.9% for the reusable device (difference ?9.5%; p = 0.200). 40.0% versus 29.5% found the respective devices very easy (difference 10.5%; p = 0.203).Conclusions: Most patients found both autoinjectors easy or very easy to use. Having two viable options may help accommodate patient preferences. Ease of administration and patient satisfaction relates to adherence; satisfied patients may more likely be adherent.Trial registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT02019550). 相似文献
80.